Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

By Ekta Bagri | July 02, 2025, 9:28 AM

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Exelixis, Inc. (EXEL): Free Stock Analysis Report

Alkermes plc (ALKS): Free Stock Analysis Report

Verona Pharma PLC American Depositary Share (VRNA): Free Stock Analysis Report

Kiniksa Pharmaceuticals International, plc (KNSA): Free Stock Analysis Report

Immunocore Holdings PLC Sponsored ADR (IMCR): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Mentioned In This Article

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Latest News

Oct-16	Workday downgraded, Fox Corp. upgraded: Wall Street's top analyst calls ALKS The Fly
Oct-15	Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 EXEL Business Wire
Oct-15	Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI - its first tissue-specific autoimmune candidate - for patients with type 1 diabetes IMCR GlobeNewswire
Oct-14	Biotech Stocks To Watch: Regeneron Partner Has Breakout In Sight KNSA Investor's Business Daily
Oct-14	Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda EXEL PR Newswire
Oct-13	Alkermes to Present New Data on Alixorexton and LUMRYZ (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research ALKS Business Wire
Oct-12	GameStop Upgraded, Celestica Downgraded: Updated Rankings on Top Blue-Chip Stocks EXEL InvestorPlace
Oct-07	Is Exelixis Stock Engineered To Make You Money? EXEL Trefis
Sep-30	Exelixis Shares Rising on CABOMETYX Revenue EXEL FX Empire
Sep-22	An orexin drugs proof-of-concept in ADHD; Cues unwarranted share slide ALKS BioPharma Dive
Sep-21	How Alkermes Used Its Narcolepsy Playbook In ADHD - And Seemingly Won ALKS Investor's Business Daily
Sep-21	Alkermes Shares Rise 6.5% After Positive Phase 1b Results for ADHD Drug ALKS 7290 ALKS InvestorsHub
Sep-16	Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors ALKS Business Wire
Sep-14	Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK (tebentafusp) in previously treated advanced melanoma IMCR GlobeNewswire
Sep-11	EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review William Blair Sees More Swings In Near Term EXEL Stocktwits

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)